Nephron Pharmaceuticals automates microbial monitoring service

Growth Direct detects any potential microbial growth 50% faster than the human eye

Nephron Pharmaceuticals will now use Rapid Micro Biosystems’ new tool to automate microbial monitoring in the drug manufacturing process. The tool is called Growth Direct. As a result, the Nephron 503(b) Outsourcing division will be able to deliver critical medical supplies to hospitals faster than ever.

As the first and only growth-based system of its kind in microbial testing, Growth Direct automates the incubation, colony counting, and data entry of microbial environmental testing. Growth Direct also detects any potential microbial growth 50% faster than the human eye. Cutting detection time allows Nephron to ship critical medical supplies to hospitals faster than using traditional microbial testing methods.

"We work hard day in and out to deliver safe, effective and affordable life-saving medications as efficiently as possible," said Nephron CEO Lou Kennedy. “Automating our microbial monitoring process allows us to produce safer drugs faster and decreases the shortage of opioid-free pain medication currently facing our nation's hospitals."

Nephron 503(b) Outsourcing is a division of Nephron Pharmaceuticals Corporation. This division produces pre-filled sterile syringes and IV bags for hospitals across America, in an effort to alleviate their drug shortage needs.

"We're excited that Nephron Pharmaceuticals Corporation has joined the growing list of global pharmaceutical manufacturers who are upgrading and automating their QC Microbial testing methods with the Growth Direct," states Rob Spignesi CEO of Rapid Micro Biosystems. "And we are proud to help Nephron Pharmaceuticals reduce the shortage of important drugs that help make surgery safer and less painful for patients across the country."

Companies